Ipamorelin (10mg)

Selective ghrelin-receptor (GHS-R1a) agonist pentapeptide. Ipamorelin is a growth-hormone secretagogue of five amino acids that switches on the ghrelin receptor. What marks it out within the GHRP family is how clean it is: the first characterisation showed it releasing growth hormone while leaving the cortisol, prolactin and ACTH responses of GHRP-6 and GHRP-2 behind.

GH pulsatility: a selective secretagogue action that spares cortisol. Bone research: bone mineral density studied in rodent models. Gastric motility: studies in post-operative ileus. Combination designs: run together with GHRH analogues. The selectivity profile was laid out by Raun et al. (Eur J Endocrinol 1998) in rats and pigs. Ipamorelin reached a completed Phase 2 trial for post-operative ileus that was not taken further. Bone density and gastric motility are the focus of the preclinical work.

Pharmacology work recorded a selective GH pulse with no cortisol or prolactin release, and rodent studies logged gains in bone mineral density and gastric motility. No human body-composition trial has been published.

The events noted across the pharmacology and ileus studies were mild, such as headache and flushing after dosing. There are no long-term human data.

In the published Ipamorelin research, the amounts used were 0.03 mg/kg i.v. infusion, Twice daily in human, adults after bowel resection (Beck DE et al. (2014)); 4.21, 14.02, 42.13, 84.27 or 140.45 nmol/kg i.v. over 15 min, Single infusion in human, healthy men (8 per dose level) (Gobburu JV et al. (1999)); 0.01–1 mg/kg i.v. bolus, Once, or four times a day at 3-h intervals in rat, postoperative ileus model (Venkova K et al. (2009)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies Ipamorelin for in-vitro research and does not give dosing guidance for people.

The two sit on different receptors (ghrelin versus GHRH), and they are combined because together the GH pulse outstrips either one.

Sermorelin is a GHRH analogue while ipamorelin is a ghrelin-receptor agonist. Sermorelin brings a clinical history; ipamorelin brings tighter receptor selectivity.

Tesamorelin, a GHRH analogue, has visceral-fat trial data; ipamorelin has no comparable outcome trial.

Each one hits a different receptor, ipamorelin the ghrelin receptor and CJC-1295 the GHRH receptor, and pharmacology studies show the joint pulse beating what either produces on its own. We carry a standalone CJC-1295 (no DAC) vial as well as a ready-blended 10mg vial.

Add about 2 mL of bacteriostatic water slowly down the inside of the vial and swirl gently; do not shake. 10mg in 2 mL gives 5 mg/mL. Refrigerate at 2–8 °C after reconstitution and use within 8–12 weeks. The calculator has this vial preset.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

The Therapeutic Goods Administration (TGA) has not registered Ipamorelin as a medicine in Australia, and it carries no approval for use in humans or animals. What Peptide Aus sells is a research reagent intended for in-vitro laboratory work and nothing more. In Australia, supplying any substance for human use falls under the Therapeutic Goods Act and the Poisons Standard, and it is the purchaser who must ensure the material is used within the law. Anyone seeking treatment should consult a doctor.

Directly from Peptide Aus, from Australian stock: Ipamorelin (10mg) is $89.99 AUD including GST. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.